Developer docs
API playgroundTry for free, no card

Search company profiles

Leinco Technologies

Full company profile

uuid0002xrg

Namestring
Leinco Technologies
Legal namestring
Leinco Technologies, Inc.
Websiteurl
leinco.com
Company typeenum
Private
Founded yearint
1992
Descriptiontext

Leinco Technologies is a privately held biotechnology company founded in 1992 and headquartered in Fenton (St. Louis), Missouri, specializing in the manufacture of early discovery research products — primarily monoclonal and polyclonal antibodies, recombinant proteins, cytokines, ELISA kits, and IVD raw materials — alongside custom CDMO services for life science researchers, IVD manufacturers, and biopharmaceutical companies. The company's core technology stack includes proprietary hybridoma development (mouse, rat, rabbit), mammalian transient expression using HEK293 and CHO systems, BriClone/BriClone-SF hybridoma cloning platforms, and purification methods spanning Protein A/G affinity and ion-exchange chromatography. It operates from an ISO 9001:2015 and ISO 13485:2016 certified facility under cGMP conditions, supporting production of in vivo functional grade antibodies (PLATINUM™ and GOLD™), custom conjugations (FITC, PE, biotin, HRP, NIR-SHIELD™), and a growing portfolio in spatial biology (PhenoCycler-Fusion/CODEX® validated and barcoded antibodies).

The company generates revenue through three streams: catalog antibody and protein product sales (publicly listed unit pricing from ~$75 to $3,375 with tiered bulk discounts and a 'mAb Advantage Pricing' program), quote-based custom CDMO services spanning hybridoma development through cGMP manufacturing, and IVD raw materials supply (matched pair antibodies, antigens, conjugates, assay buffers). GTM is primarily direct-to-customer via leinco.com e-commerce with phone/email support, supplemented by a global network of authorized distributors. Leinco is backed by private equity firm Ampersand Capital Partners, completed acquisitions of QED Biosciences and the Genovis antibody business in 2024, and announced a strategic collaboration with CellCarta in April 2026 to integrate its antibody portfolio into immuno-oncology proteomics workflows.

Short descriptiontext

Leinco Technologies is a St. Louis-based, PE-backed manufacturer of antibodies, recombinant proteins, and IVD raw materials founded in 1992, serving life science researchers, IVD manufacturers, and biopharmaceutical companies with catalog products and custom CDMO services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFenton, United States
HQ citystring
Fenton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibodies, recombinant proteins, antibody manufacturing, IVD raw materials, custom antibody services
Industry1 code
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Life Science Research Reagents (Antibodies and Proteins)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Catalog Antibody and Protein Products
TypeOne Time License
Description

Leinco generates revenue from the sale of catalog monoclonal and polyclonal antibodies, recombinant proteins, ELISA kits, assay buffers, and reagents. Products are sold in various sizes with tiered pricing (e.g., 1mg to 100mg quantities) at publicly listed prices. The company also offers conjugated formats (FITC, PE, biotin, HRP) and isotype controls.

leinco.com
2Custom CDMO Services
TypeProfessional Services
Description

Leinco provides contract development and manufacturing services including custom antibody development, monoclonal antibody manufacturing, recombinant protein production, cell banking, conjugation services, and immunoassay development. These services are quote-based and typically involve multi-step processes from planning through cGMP manufacturing.

leinco.com
3IVD Raw Materials
TypeOne Time License
Description

Leinco supplies IVD antibodies, matched pair antibodies, antigens, and conjugates for use in diagnostic immunoassays including lateral flow tests and ELISA, positioned as raw materials for further manufacturing.

leinco.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details4 tiers
1Small quantity research antibodies (µg to 5mg)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Entry-level sizes typically 50µg to 5mg, priced from approximately $75-$470 depending on product and conjugate format.

leinco.com
2Mid-range quantities (25mg to 50mg)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Mid-size quantities for larger research needs, priced from approximately $1,150-$2,350 for standard grades.

leinco.com
3Bulk quantities (100mg)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

100mg bulk quantities available at discounted per-unit pricing, ranging from approximately $2,575-$3,375 depending on quality grade (GOLD™ vs PLATINUM™).

leinco.com
4Custom services and bulk IVD manufacturing
ModelOtherBilling cadenceMulti-year contract
Notes

Custom services including CDMO, assay development, and large-scale IVD manufacturing require quote-based pricing through production request form.

leinco.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Leinco Technologies manufactures and sells catalog monoclonal and polyclonal antibodies, recombinant proteins, cytokines, ELISA kits, IVD raw materials (matched pair antibodies, antigens, conjugates, assay buffers), and specialized research tools including PLATINUM™/GOLD™ functional grade antibodies and PhenoCycler-Fusion (CODEX)® validated antibodies. The company also provides custom CDMO services covering antibody development, mammalian protein production, conjugation, purification, cell banking, gene synthesis, and immunoassay development through cGMP manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Products used to generate data published in high-impact, peer-reviewed scientific journals
+1 more record
Product overview1 text field

Leinco Technologies is a biotechnology company founded in 1992 specializing in early discovery research products and custom manufacturing services for the life sciences and IVD markets. The company offers a comprehensive portfolio of antibodies (primary monoclonal, secondary, in vivo functional grade PLATINUM™ and GOLD™, isotype controls, chimeric mAbMods™, and biosimilars), recombinant proteins, cytokines, and ELISA kits. For diagnostics, Leinco provides IVD raw materials including matched pair antibodies, antigens, conjugates, and assay buffers. The portfolio also includes spatial biology products validated for PhenoCycler-Fusion (CODEX)® platforms, novel technologies like the ADAPT-3D Tissue Clearing Kit and NIR-SHIELD™ conjugation, and bispecific antibodies. Custom services span the entire development pipeline from gene synthesis, antibody development (hybridoma, B-cell sequencing, rabbit monoclonal), protein production (HEK293/CHO expression), conjugation services, purification, cell banking, through to immunoassay development and cGMP manufacturing. Products are manufactured in the company's ISO 9001:2015 and ISO 13485:2016 certified St. Louis, Missouri facility.

Product and service26 records
1Primary Monoclonal Antibodies
CategoryAntibodies — Catalog
Description

Extensive range of primary monoclonal antibodies for research enabling scientists to generate reliable, publication-quality data across multiple applications including flow cytometry, IHC, Western Blot, ELISA, and functional studies. Intended for life science researchers.

2In Vivo Functional Grade Antibodies (PLATINUM™ and GOLD™)
CategoryAntibodies — Catalog
Description

High-purity functional grade preclinical antibodies manufactured in animal-free facilities using in vitro protein-free cell culture techniques. PLATINUM™ grade features endotoxin levels <0.5 EU/mg and IDEXX IMPACT I pathogen testing; GOLD™ grade features endotoxin levels <1.0 EU/mg. Used by researchers for in vivo preclinical studies.

3Secondary Antibodies
CategoryAntibodies — Catalog
Description

Secondary polyclonal antibodies and streptavidin products absorbed to minimize species cross-reactivity, optimally conjugated for assay-specific performance. Includes IgG Affinity Purified Antibodies, Normal Serums and Gamma Globulins, and Secondary Antibodies for Non-Human Primates. For research use.

4Isotype Control Antibodies
CategoryAntibodies — Catalog
Description

Isotype-matched negative control antibodies for flow cytometry and in vivo studies, available in multiple formats including purified, conjugated (FITC, PE, APC, biotin, PerCP, DyLight conjugates), and functional grades. For research applications.

5mAbMods™ Chimeric Antibodies
CategoryAntibodies — Catalog (Sub-brand)
Description

Engineered chimeric antibodies combining constant regions from one species with variable regions from another, designed for specific research applications requiring modified effector functions. Proprietary brand offered by Leinco Technologies.

6Biosimilar Antibodies
CategoryAntibodies — Catalog
Description

High-quality recombinant human biosimilar antibodies for research use only, providing reliable tools to support therapeutic development and comparative studies.

7IVD Raw Materials (Matched Pair Antibodies, Antigens & Conjugates, Assay Buffers)
CategoryIVD Raw Materials
Description

High-quality, low cross-reactivity IVD antibodies for use in diagnostic immunoassays supporting disease detection, therapeutic monitoring, and drug screening. Includes Matched Pair Antibodies, Antigens & Conjugates, and Assay Buffers. Intended for IVD manufacturers and diagnostic kit developers.

8Recombinant Proteins, Growth Factors & Cytokines
CategoryProteins — Catalog
Description

Ultra-pure recombinant proteins tested for optimal biological activity and reproducibility, including Type I & Type II Interferons, inflammatory cytokines, and ELISA kits. For research use.

9PhenoCycler-Fusion (CODEX)® Validated Antibodies
CategoryAntibodies — Catalog
Description

Antibodies validated for use with the PhenoCycler-Fusion spatial biology platform, enabling multiplexed single-cell analysis of tissue samples through cyclic immunofluorescence imaging. For spatial biology researchers.

10PhenoCycler-Fusion (CODEX)® Barcoded Antibodies
CategoryAntibodies — Catalog
Description

Barcoded antibodies for use with the PhenoCycler-Fusion workflow, allowing sequential staining and imaging of multiple targets on the same tissue section. For spatial biology researchers.

11ADAPT-3D Tissue Clearing Kit
CategoryReagents — New Product
Description

Novel tissue clearing technology for rapid whole-mount tissue labeling, enabling 3D visualization and analysis of intact tissue samples. For research applications.

12NIR-SHIELD™ Conjugation Products and Services
CategoryAntibodies — Catalog / Services
Description

Near-infrared fluorescent dye conjugation services and products for antibody labeling, enabling detection and imaging applications in the NIR spectrum. For research and diagnostic use.

13Bispecific Antibodies
CategoryAntibodies — Catalog (New Product)
Description

Dual-targeting therapeutic molecules for research applications, enabling simultaneous binding to two different antigens. For therapeutic discovery research.

14IHC Antibodies & Reagents
CategoryReagents — Catalog
Description

Validated immunohistochemistry antibodies and reagents for precise protein visualization in tissue samples, supporting disease research and diagnostics on fresh frozen or formalin-fixed paraffin-embedded tissues.

15ELISA Kits
CategoryAssay Kits — Catalog
Description

Ready-to-use ELISA development kits and components for biomarker detection and quantification in research applications.

16TMB Substrates
CategoryReagents — Catalog
Description

Enzyme substrates for ELISA and immunoassay development providing colorimetric detection of target analytes.

17Streptavidin and UltraAvidin™
CategoryReagents — Catalog
Description

Streptavidin-based detection reagents with high binding affinity for biotinylated antibodies, optimized for various assay formats. Includes proprietary UltraAvidin™ brand products.

18Custom Antibody Development Services
CategoryCDMO Services
Description

Comprehensive custom antibody services including B-Cell Sequencing, Hybridoma Development, Rabbit Monoclonal Antibody Development, CHO Cell Bioproduction, Recombinant Antibody Production, Polyclonal Antibody Production, and Pilot-Scale Production. Quote-based CDMO service.

19Conjugation Services
CategoryCDMO Services
Description

Custom conjugation services including Antibody Conjugation for IVD, Antibody Oligonucleotide Conjugation, Biotinylation, Fluorescent Reporter Conjugation, NIR-SHIELD™ Conjugation, and Synthetic Nanoparticle Conjugation. Quote-based service.

20Immunoassay Development Services
CategoryCDMO Services
Description

Full-service immunoassay development from planning through cGMP manufacturing, including antibody pairing, assay optimization, performance verification, validation, and scale-up for ELISA and lateral flow platforms. Quote-based CDMO service.

21Protein Production Services
CategoryCDMO Services
Description

Recombinant protein production using mammalian cell expression systems (HEK293 and CHO) with transient or stable expression capabilities. Quote-based CDMO service.

22Protein & Antibody Purification Services
CategoryCDMO Services
Description

Purification services including custom affinity chromatography, Protein A & G affinity chromatography, aseptic/low endotoxin purification, IgM purification, and ion-exchange chromatography with comprehensive bio-analytical testing. Quote-based service.

23Cell Banking Services
CategoryCDMO Services
Description

Master Cell Bank (MCB) and Working Cell Bank (WCB) preparation with mycoplasma testing, sterility testing, biosafety testing, and cell line authentication for consistent manufacturing. Quote-based service.

24Transient Antibody Expression
CategoryCDMO Services
Description

Mammalian transient protein expression using proprietary HEK293 and CHO expression systems for rapid production of highly biologically active antibodies and proteins. Quote-based service.

25Gene Synthesis
CategoryCDMO Services
Description

Custom gene synthesis services for generating DNA sequences for recombinant protein and antibody production. Quote-based service.

26Lateral Flow Assay Development
CategoryCDMO Services
Description

Rapid point-of-care lateral flow assay development from planning through validation phase, providing high-quality components and assay development services for IVD diagnostic and research needs. Quote-based service.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-23
Description

Leinco Technologies and CellCarta announced a strategic collaboration to advance proteomics solutions for drug development in immuno-oncology and targeted therapeutic modalities. The partnership integrates Leinco's validated antibody portfolio for immunohistochemistry and spatial biology platforms with CellCarta's Immuno-MRM assays and CPTAC antibody library. This combined offering aims to enhance sensitivity and specificity of proteomic analyses to accelerate biomarker discovery and support personalized medicine approaches.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in research antibodies and life science reagents, acquired by Danaher in 2023. Directly comparable as a catalog antibody supplier but with substantially greater catalog breadth, geographic reach, and scale than Leinco.

TypeDirect peer
Description

Global biotechnology company offering gene synthesis, peptide/protein production, antibody development, and CDMO services. Directly comparable to Leinco's custom antibody and protein production service offering with overlapping technology platforms.

TypeDirect peer
Description

China-based reagent manufacturer specializing in recombinant proteins, antibodies, and CDMO services. Directly comparable as an antibody/protein manufacturer competing globally on price-performance with overlapping IVD and research customer segments.

TypeDirect peer
Description

Specialty manufacturer of secondary antibodies, affinity-purified immunoglobulins, and conjugation reagents. Directly comparable to Leinco's secondary antibody and UltraAvidin™ product lines serving research and IVD markets.

TypeBroad incumbent
Description

Large publicly traded life sciences tools company with the R&D Systems, Novus Biologicals, Tocris, and ProteinSimple brands. Directly comparable as a manufacturer of research antibodies, recombinant proteins, cytokines, and ELISA kits serving the same academic and biopharma customer base.

6Santa Cruz Biotechnology
TypeDirect peer
Description

Long-established catalog antibody and reagent supplier serving academic researchers. Directly comparable as a specialty antibody provider competing for similar research customers, though with a different distribution model and brand positioning.

TypeDirect peer
Description

Specialty antibody and recombinant protein manufacturer offering catalog products and custom services including HEK293/CHO expression. Directly comparable to Leinco's technology platforms and customer base in research antibodies and CDMO services.

TypeDirect peer
Description

Specialty manufacturer of high-quality primary antibodies with deep coverage in cell signaling, cancer biology, and immunology. Closely comparable to Leinco in catalog antibody focus, validation standards, and academic/biopharma customer orientation.

TypeDirect peer
Description

Privately held manufacturer of antibodies, assay reagents, and custom services for life science and IVD applications. Closely comparable to Leinco in scale, business model, and customer mix including IVD raw materials and custom antibody services.

TypeBroad incumbent
Description

Diversified life sciences tools giant offering antibodies, reagents, and CDMO services through Invitrogen, Gibco, and Thermo Scientific brands. Competes broadly with Leinco across antibodies, recombinant proteins, and custom services with vastly greater scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Leinco Technologies

Life Science Research Reagents (Antibodies and Proteins)leinco.com

Leinco Technologies is a St. Louis-based, PE-backed manufacturer of antibodies, recombinant proteins, and IVD raw materials founded in 1992, serving life science researchers, IVD manufacturers, and biopharmaceutical companies with catalog products and custom CDMO services.

What Leinco Technologies does

Leinco Technologies is a privately held biotechnology company founded in 1992 and headquartered in Fenton (St. Louis), Missouri, specializing in the manufacture of early discovery research products — primarily monoclonal and polyclonal antibodies, recombinant proteins, cytokines, ELISA kits, and IVD raw materials — alongside custom CDMO services for life science researchers, IVD manufacturers, and biopharmaceutical companies. The company's core technology stack includes proprietary hybridoma development (mouse, rat, rabbit), mammalian transient expression using HEK293 and CHO systems, BriClone/BriClone-SF hybridoma cloning platforms, and purification methods spanning Protein A/G affinity and ion-exchange chromatography. It operates from an ISO 9001:2015 and ISO 13485:2016 certified facility under cGMP conditions, supporting production of in vivo functional grade antibodies (PLATINUM™ and GOLD™), custom conjugations (FITC, PE, biotin, HRP, NIR-SHIELD™), and a growing portfolio in spatial biology (PhenoCycler-Fusion/CODEX® validated and barcoded antibodies).

The company generates revenue through three streams: catalog antibody and protein product sales (publicly listed unit pricing from ~$75 to $3,375 with tiered bulk discounts and a 'mAb Advantage Pricing' program), quote-based custom CDMO services spanning hybridoma development through cGMP manufacturing, and IVD raw materials supply (matched pair antibodies, antigens, conjugates, assay buffers). GTM is primarily direct-to-customer via leinco.com e-commerce with phone/email support, supplemented by a global network of authorized distributors. Leinco is backed by private equity firm Ampersand Capital Partners, completed acquisitions of QED Biosciences and the Genovis antibody business in 2024, and announced a strategic collaboration with CellCarta in April 2026 to integrate its antibody portfolio into immuno-oncology proteomics workflows.

Leinco Technologies firmographics

Firmographics
Name
Leinco Technologies
Legal name
Leinco Technologies, Inc.
Website
https://leinco.com
Company type
Private
Founded year
1992
Operating status
Operating
Headcount range
11–50 employees
Short description
Leinco Technologies is a St. Louis-based, PE-backed manufacturer of antibodies, recombinant proteins, and IVD raw materials founded in 1992, serving life science researchers, IVD manufacturers, and biopharmaceutical companies with catalog products and custom CDMO services.
Ownership category
akta.pro rank

Leinco Technologies industry classification

Industry
Product category
Life Science Research Reagents (Antibodies and Proteins)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)

Keywords

  • Monoclonal antibodies
  • Recombinant proteins
  • Antibody manufacturing
  • IVD raw materials
  • Custom antibody services

Where Leinco Technologies is headquartered

Location

Headquarters

HQ city
Fenton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Leinco Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Catalog Antibody and Protein Products: Leinco generates revenue from the sale of catalog monoclonal and polyclonal antibodies, recombinant proteins, ELISA kits, assay buffers, and reagents. Products are sold in various sizes with tiered pricing (e.g., 1mg to 100mg quantities) at publicly listed prices. The company also offers conjugated formats (FITC, PE, biotin, HRP) and isotype controls.
  2. Custom CDMO Services: Leinco provides contract development and manufacturing services including custom antibody development, monoclonal antibody manufacturing, recombinant protein production, cell banking, conjugation services, and immunoassay development. These services are quote-based and typically involve multi-step processes from planning through cGMP manufacturing.
  3. IVD Raw Materials: Leinco supplies IVD antibodies, matched pair antibodies, antigens, and conjugates for use in diagnostic immunoassays including lateral flow tests and ELISA, positioned as raw materials for further manufacturing.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goSmall quantity research antibodies (µg to 5mg)
Unit PricingPay-as-you-goMid-range quantities (25mg to 50mg)
Unit PricingPay-as-you-goBulk quantities (100mg)
OtherMulti-year contractCustom services and bulk IVD manufacturing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Leinco Technologies product offering

Product offering

Core offering

Leinco Technologies manufactures and sells catalog monoclonal and polyclonal antibodies, recombinant proteins, cytokines, ELISA kits, IVD raw materials (matched pair antibodies, antigens, conjugates, assay buffers), and specialized research tools including PLATINUM™/GOLD™ functional grade antibodies and PhenoCycler-Fusion (CODEX)® validated antibodies. The company also provides custom CDMO services covering antibody development, mammalian protein production, conjugation, purification, cell banking, gene synthesis, and immunoassay development through cGMP manufacturing.

Product overview

Leinco Technologies is a biotechnology company founded in 1992 specializing in early discovery research products and custom manufacturing services for the life sciences and IVD markets. The company offers a comprehensive portfolio of antibodies (primary monoclonal, secondary, in vivo functional grade PLATINUM™ and GOLD™, isotype controls, chimeric mAbMods™, and biosimilars), recombinant proteins, cytokines, and ELISA kits. For diagnostics, Leinco provides IVD raw materials including matched pair antibodies, antigens, conjugates, and assay buffers. The portfolio also includes spatial biology products validated for PhenoCycler-Fusion (CODEX)® platforms, novel technologies like the ADAPT-3D Tissue Clearing Kit and NIR-SHIELD™ conjugation, and bispecific antibodies. Custom services span the entire development pipeline from gene synthesis, antibody development (hybridoma, B-cell sequencing, rabbit monoclonal), protein production (HEK293/CHO expression), conjugation services, purification, cell banking, through to immunoassay development and cGMP manufacturing. Products are manufactured in the company's ISO 9001:2015 and ISO 13485:2016 certified St. Louis, Missouri facility.

Differentiator

Problem solved

Functional benefit

Products and services

  • Primary Monoclonal Antibodies Extensive range of primary monoclonal antibodies for research enabling scientists to generate reliable, publication-quality data across multiple applications including flow cytometry, IHC, Western Blot, ELISA, and functional studies. Intended for life science researchers.
  • In Vivo Functional Grade Antibodies (PLATINUM™ and GOLD™) High-purity functional grade preclinical antibodies manufactured in animal-free facilities using in vitro protein-free cell culture techniques. PLATINUM™ grade features endotoxin levels <0.5 EU/mg and IDEXX IMPACT I pathogen testing; GOLD™ grade features endotoxin levels <1.0 EU/mg. Used by researchers for in vivo preclinical studies.
  • Secondary Antibodies Secondary polyclonal antibodies and streptavidin products absorbed to minimize species cross-reactivity, optimally conjugated for assay-specific performance. Includes IgG Affinity Purified Antibodies, Normal Serums and Gamma Globulins, and Secondary Antibodies for Non-Human Primates. For research use.
  • Isotype Control Antibodies Isotype-matched negative control antibodies for flow cytometry and in vivo studies, available in multiple formats including purified, conjugated (FITC, PE, APC, biotin, PerCP, DyLight conjugates), and functional grades. For research applications.
  • mAbMods™ Chimeric Antibodies Engineered chimeric antibodies combining constant regions from one species with variable regions from another, designed for specific research applications requiring modified effector functions. Proprietary brand offered by Leinco Technologies.
  • Biosimilar Antibodies High-quality recombinant human biosimilar antibodies for research use only, providing reliable tools to support therapeutic development and comparative studies.
  • IVD Raw Materials (Matched Pair Antibodies, Antigens & Conjugates, Assay Buffers) High-quality, low cross-reactivity IVD antibodies for use in diagnostic immunoassays supporting disease detection, therapeutic monitoring, and drug screening. Includes Matched Pair Antibodies, Antigens & Conjugates, and Assay Buffers. Intended for IVD manufacturers and diagnostic kit developers.
  • Recombinant Proteins, Growth Factors & Cytokines Ultra-pure recombinant proteins tested for optimal biological activity and reproducibility, including Type I & Type II Interferons, inflammatory cytokines, and ELISA kits. For research use.
  • PhenoCycler-Fusion (CODEX)® Validated Antibodies Antibodies validated for use with the PhenoCycler-Fusion spatial biology platform, enabling multiplexed single-cell analysis of tissue samples through cyclic immunofluorescence imaging. For spatial biology researchers.
  • PhenoCycler-Fusion (CODEX)® Barcoded Antibodies Barcoded antibodies for use with the PhenoCycler-Fusion workflow, allowing sequential staining and imaging of multiple targets on the same tissue section. For spatial biology researchers.
  • ADAPT-3D Tissue Clearing Kit Novel tissue clearing technology for rapid whole-mount tissue labeling, enabling 3D visualization and analysis of intact tissue samples. For research applications.
  • NIR-SHIELD™ Conjugation Products and Services Near-infrared fluorescent dye conjugation services and products for antibody labeling, enabling detection and imaging applications in the NIR spectrum. For research and diagnostic use.
  • Bispecific Antibodies Dual-targeting therapeutic molecules for research applications, enabling simultaneous binding to two different antigens. For therapeutic discovery research.
  • IHC Antibodies & Reagents Validated immunohistochemistry antibodies and reagents for precise protein visualization in tissue samples, supporting disease research and diagnostics on fresh frozen or formalin-fixed paraffin-embedded tissues.
  • ELISA Kits Ready-to-use ELISA development kits and components for biomarker detection and quantification in research applications.
  • TMB Substrates Enzyme substrates for ELISA and immunoassay development providing colorimetric detection of target analytes.
  • Streptavidin and UltraAvidin™ Streptavidin-based detection reagents with high binding affinity for biotinylated antibodies, optimized for various assay formats. Includes proprietary UltraAvidin™ brand products.
  • Custom Antibody Development Services Comprehensive custom antibody services including B-Cell Sequencing, Hybridoma Development, Rabbit Monoclonal Antibody Development, CHO Cell Bioproduction, Recombinant Antibody Production, Polyclonal Antibody Production, and Pilot-Scale Production. Quote-based CDMO service.
  • Conjugation Services Custom conjugation services including Antibody Conjugation for IVD, Antibody Oligonucleotide Conjugation, Biotinylation, Fluorescent Reporter Conjugation, NIR-SHIELD™ Conjugation, and Synthetic Nanoparticle Conjugation. Quote-based service.
  • Immunoassay Development Services Full-service immunoassay development from planning through cGMP manufacturing, including antibody pairing, assay optimization, performance verification, validation, and scale-up for ELISA and lateral flow platforms. Quote-based CDMO service.
  • Protein Production Services Recombinant protein production using mammalian cell expression systems (HEK293 and CHO) with transient or stable expression capabilities. Quote-based CDMO service.
  • Protein & Antibody Purification Services Purification services including custom affinity chromatography, Protein A & G affinity chromatography, aseptic/low endotoxin purification, IgM purification, and ion-exchange chromatography with comprehensive bio-analytical testing. Quote-based service.
  • Cell Banking Services Master Cell Bank (MCB) and Working Cell Bank (WCB) preparation with mycoplasma testing, sterility testing, biosafety testing, and cell line authentication for consistent manufacturing. Quote-based service.
  • Transient Antibody Expression Mammalian transient protein expression using proprietary HEK293 and CHO expression systems for rapid production of highly biologically active antibodies and proteins. Quote-based service.
  • Gene Synthesis Custom gene synthesis services for generating DNA sequences for recombinant protein and antibody production. Quote-based service.
  • Lateral Flow Assay Development Rapid point-of-care lateral flow assay development from planning through validation phase, providing high-quality components and assay development services for IVD diagnostic and research needs. Quote-based service.

Quantifiable outcome

  • Products used to generate data published in high-impact, peer-reviewed scientific journals
  • +1 more outcomes

Companies that use Leinco Technologies

Customer profile

Segments3 records

Ideal customer profiles3 records

Leinco Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Leinco Technologies partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CellCartacoreStrategic or Co-development Partner · 23 April 2026Leinco Technologies and CellCarta announced a strategic collaboration to advance proteomics solutions for drug development in immuno-oncology and targeted therapeutic modalities. The partnership integrates Leinco's validated antibody portfolio for immunohistochemistry and spatial biology platforms with CellCarta's Immuno-MRM assays and CPTAC antibody library. This combined offering aims to enhance sensitivity and specificity of proteomic analyses to accelerate biomarker discovery and support personalized medicine approaches.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Leinco Technologies competitors and assessment

Company assessment

Broad incumbents

  • Abcam (Danaher): Global leader in research antibodies and life science reagents, acquired by Danaher in 2023. Directly comparable as a catalog antibody supplier but with substantially greater catalog breadth, geographic reach, and scale than Leinco.
  • Bio-Techne: Large publicly traded life sciences tools company with the R&D Systems, Novus Biologicals, Tocris, and ProteinSimple brands. Directly comparable as a manufacturer of research antibodies, recombinant proteins, cytokines, and ELISA kits serving the same academic and biopharma customer base.
  • Thermo Fisher Scientific (Life Sciences Solutions): Diversified life sciences tools giant offering antibodies, reagents, and CDMO services through Invitrogen, Gibco, and Thermo Scientific brands. Competes broadly with Leinco across antibodies, recombinant proteins, and custom services with vastly greater scale.

Direct peers

  • GenScript: Global biotechnology company offering gene synthesis, peptide/protein production, antibody development, and CDMO services. Directly comparable to Leinco's custom antibody and protein production service offering with overlapping technology platforms.
  • Sino Biological: China-based reagent manufacturer specializing in recombinant proteins, antibodies, and CDMO services. Directly comparable as an antibody/protein manufacturer competing globally on price-performance with overlapping IVD and research customer segments.
  • Jackson ImmunoResearch: Specialty manufacturer of secondary antibodies, affinity-purified immunoglobulins, and conjugation reagents. Directly comparable to Leinco's secondary antibody and UltraAvidin™ product lines serving research and IVD markets.
  • Santa Cruz Biotechnology: Long-established catalog antibody and reagent supplier serving academic researchers. Directly comparable as a specialty antibody provider competing for similar research customers, though with a different distribution model and brand positioning.
  • OriGene Technologies: Specialty antibody and recombinant protein manufacturer offering catalog products and custom services including HEK293/CHO expression. Directly comparable to Leinco's technology platforms and customer base in research antibodies and CDMO services.
  • Cell Signaling Technology (CST): Specialty manufacturer of high-quality primary antibodies with deep coverage in cell signaling, cancer biology, and immunology. Closely comparable to Leinco in catalog antibody focus, validation standards, and academic/biopharma customer orientation.
  • Rockland Immunochemicals: Privately held manufacturer of antibodies, assay reagents, and custom services for life science and IVD applications. Closely comparable to Leinco in scale, business model, and customer mix including IVD raw materials and custom antibody services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Leinco Technologies social profiles

Digital presence

Leinco Technologies compliance and trust

Trust signal

Compliance2 records

Leinco Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Leinco Technologies leadership team

Management profile

Number of profiles

Profiles1 record

Leinco Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Leinco Technologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Leinco Technologies M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leinco Technologies

What does Leinco Technologies do?

Leinco Technologies manufactures and sells catalog monoclonal and polyclonal antibodies, recombinant proteins, cytokines, ELISA kits, IVD raw materials (matched pair antibodies, antigens, conjugates, assay buffers), and specialized research tools including PLATINUM™/GOLD™ functional grade antibodies and PhenoCycler-Fusion (CODEX)® validated antibodies. The company also provides custom CDMO services covering antibody development, mammalian protein production, conjugation, purification, cell banking, gene synthesis, and immunoassay development through cGMP manufacturing.

Is Leinco Technologies a public or private company?

Leinco Technologies is a private company. It is classified as private equity controlled and is currently operating.

When was Leinco Technologies founded?

Leinco Technologies was founded in 1992. It employs 11 to 50 people.

Where is Leinco Technologies based?

Leinco Technologies is headquartered in Fenton, United States, in the North America region.

How does Leinco Technologies make money?

Three revenue lines are on record. Catalog Antibody and Protein Products are the primary driver. The others are custom CDMO Services and IVD Raw Materials.

Who are Leinco Technologies's main competitors?

Broad incumbents on record are Abcam (Danaher), Bio-Techne and Thermo Fisher Scientific (Life Sciences Solutions). Direct peers are GenScript, Sino Biological, Jackson ImmunoResearch, Santa Cruz Biotechnology, OriGene Technologies, Cell Signaling Technology (CST) and Rockland Immunochemicals.

Does Leinco Technologies have an API?

No public API is recorded for Leinco Technologies.

What industry is Leinco Technologies in?

Leinco Technologies's product category is Life Science Research Reagents (Antibodies and Proteins). Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 325414 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireWestern Blotting Market Surges with 9% CAGR, Driven by Automation and High-Sensitivity Protein AnalysisThe western blotting market is projected to grow from $1.39 billion in 2025 to $1.52 billion in 2026, reaching $2.14 billion by 2030, driven by increased life science research, pharmaceutical investments, and rising demand for biomarker-based diagnostics. Key recent company actions include Leinco Technologies' acquisition of QED Biosciences in September 2024 to enhance its antibody offerings, and Bio-Rad's launch of the ChemiDoc Go Imaging System in July 2024 featuring CMOS digital imaging technology. The market faces headwinds from tariffs increasing costs for imported instruments and consumables, though this has spurred domestic production and innovation in cost-efficient technologies.EIN PresswireWho’s Ahead in the Chimeric Antibody Market? Competitive Insights for 2026F. Hoffmann-La Roche led global chimeric antibody sales in 2024 with a 13% market share, followed by Johnson & Johnson at 12%. The top 10 players held 30% of total revenue, and companies are focusing on advanced antibody engineering and biosimilar development to strengthen competitive positioning.openPR.comRabbit Monoclonal Antibody Market Overview, Key Trends, and Insights on Major PlayersThe rabbit monoclonal antibody market is projected to reach $1.46 billion by 2030, growing at a compound annual growth rate of 9.6%, driven by rising demand for precise diagnostic tools, increased usage in drug discovery, and adoption of recombinant antibody technologies. In September 2024, Leinco Technologies Inc., a US-based biotech firm, acquired QED Biosciences Inc. to enhance its antibody production capabilities and strengthen its position in the rabbit monoclonal antibody segment. Additionally, ImmunoPrecise Antibodies Ltd., a Canada-based AI-driven biotech company, announced significant breakthroughs in its rabbit antibody platforms using its B Cell Select platform integrated with LENSai artificial intelligence technology.GlobeNewswireLeinco Technologies and CellCarta Collaborate to Advance Proteomics Solutions and Applications for Drug DevelopmentLeinco Technologies and CellCarta announced a strategic collaboration to advance proteomics solutions for immuno-oncology and targeted therapies. The partnership combines Leinco's validated antibodies with CellCarta's Immuno-MRM assays, enabling precise protein measurements for biomarker discovery and clinical research.GlobeNewswireLeinco Technologies and CellCarta Collaborate to Advance Proteomics Solutions and Applications for Drug DevelopmentLeinco Technologies and CellCarta announced a strategic collaboration to advance proteomics solutions for drug development in immuno-oncology and targeted therapeutic modalities. The partnership integrates Leinco's validated antibody portfolio for immunohistochemistry and spatial biology platforms with CellCarta's Immuno-MRM assays and CPTAC antibody library. This combined offering aims to enhance sensitivity and specificity of proteomic analyses to accelerate biomarker discovery and support personalized medicine approaches.EIN PresswireLeinco Technologies and CellCarta collaborate to advance proteomics solutions and applications for drug developmentLeinco Technologies and CellCarta announced a collaboration combining Leinco's validated antibodies for IHC and spatial analysis with CellCarta's CPTAC antibodies for Immuno-MRM assays. The partnership aims to enhance proteomic sensitivity and specificity for biomarker discovery and drug development, particularly in immuno-oncology.openPR.comSegmentation Analysis, Market Trends, and Competitive Landscape in the Western Blotting MarketThe western blotting market is projected to reach $2.14 billion by 2030, growing at a compound annual growth rate of 9.0%, driven by rising demand for biomarker-based diagnostics and increased proteomics research. In September 2024, US-based biotech firm Leinco Technologies Inc. acquired QED Biosciences to expand its portfolio in antibodies and recombinant proteins for western blotting applications. Additionally, Bio-Rad launched the ChemiDoc Go Imaging System in July 2024, featuring CMOS digital imaging and stain-free technology for enhanced protein analysis.BioSpaceLeinco Technologies Awarded $1M Grant to Develop Rapid Test for Intestinal Immunity to PolioLeinco Technologies received a $1M Gates Foundation grant to develop a rapid field assay for intestinal immune response to poliovirus. The test aims to improve monitoring of vaccination campaigns and identify polio-exposed communities. The company will focus on creating a scalable, field-deployable diagnostic tool.Leinco$1M Grant to Develop Rapid Test for PolioLeinco Technologies received a $1M Gates Foundation grant to develop a rapid field assay for intestinal immunity to polio. The test aims to monitor vaccination campaigns and identify polio-exposed communities, potentially improving eradication efforts in high-risk settings.BenzingaLeinco Technologies Inc. Acquires QED Biosciences, Leading Provider of Antibodies, Related Reagents, andLeinco Technologies Inc. has acquired QED Biosciences, a leading provider of antibodies and reagents previously owned by Genovis, to expand its portfolio in the IVD and research sectors. This acquisition is backed by private equity firm Ampersand Capital Partners and aims to strengthen Leinco's position as a global leader in antibody markets through integrated capabilities.